Literature DB >> 18632632

Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.

Jinlu Dai1, Christopher L Hall, June Escara-Wilke, Atsushi Mizokami, Jill M Keller, Evan T Keller.   

Abstract

Prostate cancer (PCa) is frequently accompanied by osteosclerotic (i.e., excessive bone production) bone metastases. Although bone morphogenetic proteins (BMP) and Wnts are mediators of PCa-induced osteoblastic activity, the relation between them in PCa bone metastases is unknown. The goal of this study was to define this relationship. Wnt3a and Wnt5a administration or knockdown of DKK-1, a Wnt inhibitor, induced BMP-4 and 6 expression and promoter activation in PCa cells. DKK-1 blocked Wnt activation of the BMP promoters. Transfection of C4-2B cells with axin, an inhibitor of canonical Wnt signaling, blocked Wnt3a but not Wnt5a induction of the BMP promoters. In contrast, Jnk inhibitor I blocked Wnt5a but not Wnt3a induction of the BMP promoters. Wnt3a, Wnt5a, and conditioned medium (CM) from C4-2B or LuCaP23.1 cells induced osteoblast differentiation in vitro. The addition of DKK-1 and Noggin, a BMP inhibitor, to CM diminished PCa CM-induced osteoblast differentiation in a synergistic fashion. However, pretreatment of PCa cells with DKK-1 before collecting CM blocked osteoblast differentiation, whereas pretreatment with Noggin only partially reduced osteoblast differentiation, and pretreatment with both DKK-1 and Noggin had no greater effect than pretreatment with DKK-1 alone. Additionally, knockdown of BMP expression in C4-2B cells inhibited Wnt-induced osteoblastic activity. These results show that PCa promotes osteoblast differentiation through canonical and noncanonical Wnt signaling pathways that stimulate both BMP-dependent and BMP-independent osteoblast differentiation. These results show a clear link between Wnts and BMPs in PCa-induced osteoblast differentiation and provide novel targets, including the noncanonical Wnt pathway, for therapy of PCa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632632      PMCID: PMC4432935          DOI: 10.1158/0008-5472.CAN-07-6541

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade.

Authors:  J B Nelson; S H Nguyen; J R Wu-Wong; T J Opgenorth; D B Dixon; L W Chung; N Inoue
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

2.  Ectodermal Wnt3/beta-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge.

Authors:  Jeffery R Barrow; Kirk R Thomas; Oreda Boussadia-Zahui; Robert Moore; Rolf Kemler; Mario R Capecchi; Andrew P McMahon
Journal:  Genes Dev       Date:  2003-02-01       Impact factor: 11.361

3.  Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms.

Authors:  K L Weber; M E Bolander; M G Rock; D Pritchard; G Sarkar
Journal:  J Orthop Res       Date:  1998-01       Impact factor: 3.494

4.  Characterization of human bone morphogenetic protein (BMP)-4 and -7 gene promoters: activation of BMP promoters by Gli, a sonic hedgehog mediator.

Authors:  S Kawai; T Sugiura
Journal:  Bone       Date:  2001-07       Impact factor: 4.398

5.  Prostate cancer cells promote osteoblastic bone metastases through Wnts.

Authors:  Christopher L Hall; Anna Bafico; Jinlu Dai; Stuart A Aaronson; Evan T Keller
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

6.  Regulation of the promoters for the human bone morphogenetic protein 2 and 4 genes.

Authors:  L M Helvering; R L Sharp; X Ou; A G Geiser
Journal:  Gene       Date:  2000-10-03       Impact factor: 3.688

7.  Effect of 1,25(OH)2D3 on bone morphogenetic protein-3 mRNA expression.

Authors:  C Faucheux; R Bareille; J Amédée; J T Triffitt
Journal:  J Cell Biochem       Date:  1999-04-01       Impact factor: 4.429

8.  Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death.

Authors:  C Bonny; A Oberson; S Negri; C Sauser; D F Schorderet
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

9.  Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression.

Authors:  Lorenz Haegele; Barbara Ingold; Heike Naumann; Ghazaleh Tabatabai; Birgit Ledermann; Sebastian Brandner
Journal:  Mol Cell Neurosci       Date:  2003-11       Impact factor: 4.314

10.  Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells.

Authors:  Roxane Tenta; Despina Tiblalexi; Evangelia Sotiriou; Peter Lembessis; Menelaos Manoussakis; Michael Koutsilieris
Journal:  Prostate       Date:  2004-05-01       Impact factor: 4.104

View more
  57 in total

1.  p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.

Authors:  Christopher L Hall; Honglai Zhang; Shobun Baile; Mats Ljungman; Stuart Kuhstoss; Evan T Keller
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

2.  Role of non-canonical Wnt signaling in osteoblast maturation on microstructured titanium surfaces.

Authors:  Rene Olivares-Navarrete; Sharon L Hyzy; Daphne L Hutton; Ginger R Dunn; Christoph Appert; Barbara D Boyan; Zvi Schwartz
Journal:  Acta Biomater       Date:  2011-02-23       Impact factor: 8.947

3.  Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.

Authors:  Srinivas Nandana; Manisha Tripathi; Peng Duan; Chia-Yi Chu; Rajeev Mishra; Chunyan Liu; Renjie Jin; Hironobu Yamashita; Majd Zayzafoon; Neil A Bhowmick; Haiyen E Zhau; Robert J Matusik; Leland W K Chung
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

Review 4.  Unravelling the complexity of metastasis - molecular understanding and targeted therapies.

Authors:  Nilay Sethi; Yibin Kang
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 5.  Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.

Authors:  Kosei Nakajima; Dong Hyo Kho; Takashi Yanagawa; Melissa Zimel; Elisabeth Heath; Victor Hogan; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

6.  An integrative model of prostate cancer interaction with the bone microenvironment.

Authors:  A Farhat; D Jiang; D Cui; E T Keller; T L Jackson
Journal:  Math Biosci       Date:  2017-09-14       Impact factor: 2.144

7.  Does Wnt/β-catenin pathway contribute to the stability of DNMT1 expression in urological cancer cell lines?

Authors:  Nuray Varol; Ece Konac; Cenk Y Bilen
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-27

8.  Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.

Authors:  Dali Zheng; Keith F Decker; Tianhua Zhou; Jianquan Chen; Zongtai Qi; Kathryn Jacobs; Katherine N Weilbaecher; Eva Corey; Fanxin Long; Li Jia
Journal:  Mol Cancer Res       Date:  2013-02-05       Impact factor: 5.852

9.  Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis.

Authors:  Joseph L Sottnik; Stephanie Daignault-Newton; Xiaotun Zhang; Colm Morrissey; Maha H Hussain; Evan T Keller; Christopher L Hall
Journal:  Clin Exp Metastasis       Date:  2012-12-15       Impact factor: 5.150

10.  The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability.

Authors:  Roberto Benelli; Stefano Monteghirfo; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari
Journal:  Mol Cancer       Date:  2010-06-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.